Patent application number | Description | Published |
20120270928 | MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY - Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer. | 10-25-2012 |
20130123329 | MICRORNA COMPOSITIONS AND METHODS - Provided herein are compositions comprising oligomeric compounds. In certain embodiments, the oligomeric compounds are useful as miRNA mimics. The oligomeric compounds may mimic the activity of miR-34. Also provided herein are methods for the treatment of cancer. | 05-16-2013 |
20130289093 | MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY - Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer. | 10-31-2013 |
20140100263 | METHODS FOR TREATMENT OF ALPORT SYNDROME - Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome. | 04-10-2014 |
20140107183 | MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY - Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer. | 04-17-2014 |
20140329887 | MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY - Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer. | 11-06-2014 |
20140350090 | MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122 - Described herein are compositions and methods for the inhibition of miR-122 activity. The compositions have certain nucleoside modifications that yield potent inhibitors of miR-122 activity. The compounds may comprise conjugates to facilitate delivery to the liver. The compositions may be administered to subjects infected with hepatitis C virus, as a treatment for hepatitis C virus and related conditions. | 11-27-2014 |
20150031130 | COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE - Described herein are conjugated modified oligonucleotides that are complementary to a target RNA. The conjugate facilitates cellular uptake of the modified oligonucleotide, resulting improved potency. | 01-29-2015 |
20150087607 | MICRORNA COMPOSITIONS AND METHODS - Provided herein are compositions comprising oligomeric compounds. In certain embodiments, the oligomeric compounds are useful as miRNA mimics. The oligomeric compounds may mimic the activity of miR-34. Also provided herein are methods for the treatment of cancer. | 03-26-2015 |